| Literature DB >> 20422000 |
Antoine Popelut1, Fabien Valet, Olivier Fromentin, Aurélie Thomas, Philippe Bouchard.
Abstract
BACKGROUND: The number of dental implant treatments increases annually. Dental implants are manufactured by competing companies. Systematic reviews and meta-analysis have shown a clear association between pharmaceutical industry funding of clinical trials and pro-industry results. So far, the impact of industry sponsorship on the outcomes and conclusions of dental implant clinical trials has never been explored. The aim of the present study was to examine financial sponsorship of dental implant trials, and to evaluate whether research funding sources may affect the annual failure rate. METHODS ANDEntities:
Mesh:
Substances:
Year: 2010 PMID: 20422000 PMCID: PMC2858083 DOI: 10.1371/journal.pone.0010274
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Flowchart of systematic review selection.
Figure 2Flowchart of the primary article selection.
Sample characteristics.
| Characteristics | Category | Total n = 41 |
| Age of publication, tertiles | 4–10 | 31 (76%) |
| 11–15 | 9 (22%) | |
| >15 | 1 (2%) | |
| Impact factors, tertiles | Not indexed | 9 (22%) |
| 0.52–1.09 | 8 (19%) | |
| 1.10–1.67 | 15 (37%) | |
| 1.68–2.24 | 9 (22%) | |
| Corresponding author country | USA | 4 (10%) |
| Belgium | 5 (12%) | |
| Sweden | 10 (24%) | |
| Switzerland | 5 (12%) | |
| Italy | 2 (5%) | |
| England | 2 (5%) | |
| Germany | 3 (7%) | |
| Canada | 2 (5%) | |
| Others | 8 (20%) | |
| Study design | Retrospective | 10 (25%) |
| Prospective | 31 (75%) | |
| Quality assessment | Low risk of bias | 14 (34%) |
| Risk of bias | 27 (66%) | |
| Statistical advisor | Yes | 11 (27%) |
| No | 30 (73%) | |
| Prosthetic design | IS-SC | 18 (44%) |
| IS-FPD | 15 (36%) | |
| ITS-FPD | 8 (20%) | |
| Periodontal status report | Yes | 7 (17%) |
| No | 34 (83%) | |
| Total number of implants, tertiles | 10–347 | 38 (93%) |
| 348–685 | 2 (5%) | |
| 686–1022 | 1(2%) | |
| Number of failures, tertiles | 0–19 | 37 (90%) |
| 20–39 | 2 (5%) | |
| 40–58 | 2 (5%) | |
| Implant brand | Straumann | 8 (19%) |
| Astra Tech | 3 (7%) | |
| Nobel Biocare | 24 (59%) | |
| Others | 6 (15%) | |
| Funding source | Industry | 2 (5%) |
| Industry associated | 9 (22%) | |
| Non industry | 4 (10%) | |
| Unknown | 26 (63%) |
Figure 3Annual percentages of failures.
Regression quasi-Poisson univariate and multivariate models of the effects of independent variables on the annual failure rate of dental implants.
| Category | Univariate Quasi-Poisson | Multivariate Quasi-Poisson | |||||
| OR | CI 95% | p-value | OR | CI 95% | p-value | ||
| Study Age | 1.07 | [0.98–1.16] | 0.085 | 1.12 | [1.06–1.19] | 0.002 | |
| Number of Implants | 1.00 | [0.99–1.00] | 0.424 | ||||
| Impact Factor | 0.90 | [0.61–1.33] | 0.549 | ||||
| Periodontal Status Report | No | 1 | – | ||||
| Yes | 0.90 | [0.33–2.45] | 0.812 | ||||
| Prosthetic Design | ITS-FPD | 1 | – | ||||
| IS-FPD | 0.56 | [0.34–0.91] | |||||
| IS-SC | 0.34 | [0.15–0.77] | 0.023 | ||||
| Quality Score | LRB | 1 | – | ||||
| RB | 0.81 | [0.47–1.41] | 0.427 | ||||
| Statistical Advisor | No | 1 | – | ||||
| Yes | 1.54 | [0.95–2.50] | 0.082 | ||||
| Funding Source | Non-Industry Associated | 1 | – | 1 | |||
| Industry Associated | 0.32 | [0.17–0.60] | 0.21 | [0.12–0.38] | |||
| Unknown | 0.37 | [0.21–0.63] | 0.005 | 0.33 | [0.21–0.51] | <0.001 | |